Literature DB >> 28138971

Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration.

Matthew N Newmeyer1,2, Madeleine J Swortwood1,3, Megan E Taylor1, Osama A Abulseoud1, Thomas H Woodward4, Marilyn A Huestis1,5.   

Abstract

Establishing science-based driving per se blood Δ9 -tetrahydrocannabinol (THC) limits is challenging, in part because of prolonged THC detection in chronic, frequent users. Therefore, documenting observable signs of impairment is important for driving under the influence of drugs. We evaluated frequent and occasional cannabis smokers' performance on the modified Romberg balance, one leg stand (OLS), and walk and turn (WAT) tasks, and pupil size effects following controlled placebo (0.001% THC), smoked, vaporized and oral (6.9% [~50.4 mg] THC) cannabis administration. Significant effects following inhaled doses were not observed due to delayed tasks administration 1.5 and 3.5 h post-dose, but significant impairment was observed after oral dosing (blood THC concentrations peaked 1.5-3.5 h post-dose). Occasional smokers' odds of exhibiting ≥2 clues on the OLS or WAT following oral dosing were 6.4 (95% CI 2.3-18.4) times higher than after placebo, with THC and 11-hydroxy-THC blood concentrations individually producing odds ratios of 1.3 (1.1-1.5) and 1.5 (1.3-1.8) for impairment in these tasks, respectively. Pupil sizes after oral dosing under the direct lighting condition were significantly larger than after placebo by mean (SE, 95% CI) 0.4 (0.1, 0.2-0.6) mm at 1.5 h and 0.5 (0.2, 0.2-0.8) mm at 3.5 h among all participants. Oral cannabis administration impaired occasional cannabis users' performance on the OLS and WAT tasks compared to placebo, supporting other reports showing these tasks are sensitive to cannabis-related impairment. Occasional smokers' impairment was related to blood THC and 11-hydroxy-THC concentrations. These are important public health policy findings as consumption of edible cannabis products increases. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Drug Evaluation and Classification Program; cannabis; edibles; modified Romberg balance; one leg stand; performance; pupil size; walk and turn

Mesh:

Year:  2017        PMID: 28138971     DOI: 10.1002/jat.3440

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  10 in total

1.  Driving under the influence of cannabis among medical cannabis patients with chronic pain.

Authors:  Erin E Bonar; James A Cranford; Brooke J Arterberry; Maureen A Walton; Kipling M Bohnert; Mark A Ilgen
Journal:  Drug Alcohol Depend       Date:  2019-01-09       Impact factor: 4.492

2.  Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study.

Authors:  Andrew A Monte; Shelby K Shelton; Eleanor Mills; Jessica Saben; Andrew Hopkinson; Brandon Sonn; Michael Devivo; Tae Chang; Jacob Fox; Cody Brevik; Kayla Williamson; Diana Abbott
Journal:  Ann Intern Med       Date:  2019-03-26       Impact factor: 25.391

3.  Preliminary Eye-Tracking Data as a Nonintrusive Marker for Blood Δ-9-Tetrahydrocannabinol Concentration and Drugged Driving.

Authors:  Ali Shahidi Zandi; Felix J E Comeau; Robert E Mann; Patricia Di Ciano; Eliyas P Arslan; Thomas Murphy; Bernard Le Foll; Christine M Wickens
Journal:  Cannabis Cannabinoid Res       Date:  2021-08-24

4.  Eye tracking: empirical foundations for a minimal reporting guideline.

Authors:  Kenneth Holmqvist; Saga Lee Örbom; Ignace T C Hooge; Diederick C Niehorster; Robert G Alexander; Richard Andersson; Jeroen S Benjamins; Pieter Blignaut; Anne-Marie Brouwer; Lewis L Chuang; Kirsten A Dalrymple; Denis Drieghe; Matt J Dunn; Ulrich Ettinger; Susann Fiedler; Tom Foulsham; Jos N van der Geest; Dan Witzner Hansen; Samuel B Hutton; Enkelejda Kasneci; Alan Kingstone; Paul C Knox; Ellen M Kok; Helena Lee; Joy Yeonjoo Lee; Jukka M Leppänen; Stephen Macknik; Päivi Majaranta; Susana Martinez-Conde; Antje Nuthmann; Marcus Nyström; Jacob L Orquin; Jorge Otero-Millan; Soon Young Park; Stanislav Popelka; Frank Proudlock; Frank Renkewitz; Austin Roorda; Michael Schulte-Mecklenbeck; Bonita Sharif; Frederick Shic; Mark Shovman; Mervyn G Thomas; Ward Venrooij; Raimondas Zemblys; Roy S Hessels
Journal:  Behav Res Methods       Date:  2022-04-06

5.  Development and Verification of a Linked Δ 9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-05-05       Impact factor: 3.579

6.  Time to acknowledge the mixed effects of cannabis on health: a summary and critical review of the NASEM 2017 report on the health effects of cannabis and cannabinoids.

Authors:  Janna Cousijn; Adrián E Núñez; Francesca M Filbey
Journal:  Addiction       Date:  2017-12-21       Impact factor: 7.256

7.  Recent legalization of cannabis use: effects on sleep, health, and workplace safety.

Authors:  Nicole P Bowles; Maya X Herzig; Steven A Shea
Journal:  Nat Sci Sleep       Date:  2017-10-19

8.  Beyond the high: Mapping patterns of use and motives for use of cannabis as medicine.

Authors:  Sinikka L Kvamme; Michael M Pedersen; Sagi Alagem-Iversen; Birgitte Thylstrup
Journal:  Nordisk Alkohol Nark       Date:  2021-02-25

9.  Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study.

Authors:  Maureen A Leehey; Ying Liu; Felecia Hart; Christen Epstein; Mary Cook; Stefan Sillau; Jost Klawitter; Heike Newman; Cristina Sempio; Lisa Forman; Lauren Seeberger; Olga Klepitskaya; Zachrey Baud; Jacquelyn Bainbridge
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-15

10.  Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.

Authors:  Tory R Spindle; Erin L Martin; Megan Grabenauer; Thomas Woodward; Michael A Milburn; Ryan Vandrey
Journal:  J Psychopharmacol       Date:  2021-05-28       Impact factor: 4.562

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.